If clinical trials are successful and the FDA approves the drug, it could be available across the United States later in 2021
THURSDAY, April 29, 2021 (HealthDay News) — A pill to treat COVID-19 is being developed by Pfizer and could be available by the end of the year, company CEO Albert Bourla says.
In March, Pfizer launched an early-stage clinical trial of a new antiviral drug for the coronavirus that causes COVID-19, CBS News reported. The drug reduces the production of enzymes the virus needs to multiply in human cells.
If clinical trials are successful and the U.S. Food and Drug Administration approves the drug, it could be available across the United States later in 2021, Bourla told CNBC on Tuesday, CBS News reported.
Last month, Mikael Dolsten, M.D., chief scientific officer and president, worldwide research, development, and medical of Pfizer, said it is possible that the new drug could be prescribed “at the first sign of infection, without requiring that patients are hospitalized or in critical care.”
Treatment Satisfaction Higher for Patients With RA Choosing Their Own Treatment 
Drug Interactions Reducing Contraceptive Effectiveness Common in Epilepsy .jpg)
Most Specialty Oral Anticancer Meds for Blood Cancers Are Initially Rejected by Insurers 
1 in 3 With Lupus Take Supplements, Medications With Potential for Interactions 
Few Meet Major Clinical Response Criteria After Treatment Escalation for Lupus 
Postoperative Complications Elevated for Patients With Systemic Lupus Erythematosus 
Holding DMARDs at Time of COVID-19 Vaccine Not Warranted in Those With Inflammatory Arthritis 
2013 to 2024 Saw Decrease in Benzodiazepine Prescribing 
